| Name | Title | Contact Details |
|---|---|---|
Janet Martineau |
Vice President, Head of Intellectual Property | Profile |
Alexander Nguyen |
General Counsel | Profile |
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.
BioMedica, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Nitrome Biosciences has discovered and identified a new class of enzymes.
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.